Table 5 Pattern of progression following MDT
From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
Metastatic location | n (%) | Therapy | n (%) |
|---|---|---|---|
Local failure | 2 (4.4%) | ADT initiation/escalation | 2 (4.4%) |
 ≤ 5 new bone metastases | 19 (42.2%) | Repeated MDT | 10 (22.2%) |
| Â | Â | ADT initiation/escalation | 6 (13.3%) |
|  |  | Repeated MDT + ADT initiation/escalation | 3 (6.6%) |
 > 5 new bone metastases | 8 (17.7%) | ADT initiation/escalation | 5 (11.1%) |
| Â | Â | Lutetium radio-ligand therapy | 2 (4.4%) |
| Â | Â | None | 1 (2.2%) |
Lymph node recurrence | 8 (17.7%) | Salvage-RT + ADT initiation/escalation | 4 (8.8%) |
| Â | Â | ADT escalation | 3 (6.6%) |
| Â | Â | None | 1 (2.2%) |
Prostate fossa recurrence | 3 (6.6%) | Salvage-RT + ADT initiation/escalation | 2 (4.4%) |
| Â | Â | ADT initiation | 1 (2.2%) |
Visceral metastases | 2 (4.4%) | Chemotherapy initiation | 1 (2.2%) |
| Â | Â | Repeated MDT | 1 (2.2%) |
Biochemical progression only | 7 (13.3%) | ADT initiation/escalation | 3 (6.6%) |
| Â | Â | None | 4 (8.8%) |